Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

Erzin G., Topcuoglu C., Bayram S., Karadag H., ÖZKAYA G., Turhan T., ...Daha Fazla

PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, cilt.29, sa.4, ss.394-398, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1080/24750573.2019.1589175
  • Dergi Adı: PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.394-398
  • Anahtar Kelimeler: Schizophrenia, neuroendocrine, peripheral markers, DORSOLATERAL PREFRONTAL CORTEX, NEGATIVE SYNDROME SCALE, INSULIN-SECRETION, GENE-EXPRESSION, NEURONS, RELIABILITY, VALIDITY, DEFICITS, GABA
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Schizophrenia is a neurodegenerative and neurodevelopmental disorder. For this reason, it is important to determine the level of markers that are neuroprotective and have been altered in other neurodegenerative diseases in inspecting the etiology of schizophrenia. Secretagogin (SCGN), is a member of Calcium (Ca) binding proteins and thought to have a neuroprotective effect. In this study, we aimed to compare the level of secretagogin (SCGN) between age and gender-matched schizophrenia and control group.